SBFM Phase 2 readout: a negative outcome, -39.5%

On May 15, 2026, Sunshine Biopharma Inc. reached its Phase 2 readout. The result was a negative outcome, and the stock moved -39.5% in the window around the event. It had already run +5.0% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.